Alaunos Therapeutics, Inc. (NASDAQ:TCRT – Get Free Report) saw a large growth in short interest during the month of September. As of September 30th, there was short interest totaling 9,736 shares, a growth of 60.3% from the September 15th total of 6,075 shares. Currently, 0.5% of the company’s stock are short sold. Based on an average daily trading volume, of 4,314,053 shares, the short-interest ratio is currently 0.0 days.
Wall Street Analysts Forecast Growth
Separately, Weiss Ratings cut shares of Alaunos Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a report on Monday, August 17th. One investment analyst has rated the stock with a Sell rating. According to data from MarketBeat.com, Alaunos Therapeutics currently has an average rating of “Sell”.
Read Our Latest Research Report on TCRT
Alaunos Therapeutics Stock Up 20.6%
Shares of NASDAQ TCRT opened at $2.63 on Friday. The firm has a 50-day moving average price of $1.52 and a 200 day moving average price of $2.09. The stock has a market capitalization of $6.68 million, a price-to-earnings ratio of -1.38 and a beta of -0.87. Alaunos Therapeutics has a 52 week low of $0.72 and a 52 week high of $4.50.
Alaunos Therapeutics (NASDAQ:TCRT – Get Free Report) last released its quarterly earnings results on Friday, August 14th. The company reported ($0.41) earnings per share for the quarter.
Alaunos Therapeutics Company Profile
Alaunos Therapeutics, Inc is a biotechnology company focused on developing genetically engineered T-cell therapies for the treatment of cancer, particularly solid tumors. Its research centers on T-cell receptor (TCR) therapies, which are designed to equip a patient’s immune cells to recognize and attack tumor-specific targets.
The company’s development programs have included TCR-T candidates directed at cancer-associated antigens such as NY-ESO-1 and LAGE-1a. Alaunos has also worked on a TCR library approach intended to support the development of personalized therapies targeting tumor mutations.
Further Reading
- Five stocks we like better than Alaunos Therapeutics
- Rocket Lab’s Neutron Delay Leaves Wall Street Bullish But Raises the Stakes for 2027
- ManpowerGroup Stock Sinks on Q3 Results, But Fundamentals Stay Solid
- Does the AI Selloff Put Alphabet’s Breakout in Doubt?
- Bank Earnings Are Mixed—These 2 ETFs Offer Very Different Paths to a Recovery
Receive News & Ratings for Alaunos Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alaunos Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
